Biotech investors are increasingly decoupling the performance of pharmaceutical stocks from the ongoing administrative turbulence at the Food and Drug Administration (FDA) and the broader uncertainty surrounding the Make America Healthy Again (MAHA) movement. Despite heightened rhetoric regarding sweeping federal agency overhauls, the Nasdaq Biotechnology Index has maintained steady growth throughout the first quarter of…
Biotech investors are increasingly shrugging off the political turbulence surrounding the Food and Drug Administration (FDA) and the broader “Make America Healthy Again” (MAHA) movement, signaling a shift in market priorities as of late 2024. While uncertainty regarding regulatory appointments and potential agency restructuring continues to circulate in Washington, D.C., Wall Street has shifted its…
President-elect Donald Trump is reportedly moving to remove Dr. Marty Makary from his post as Commissioner of the Food and Drug Administration (FDA), according to sources familiar with the transition team’s discussions. The potential dismissal comes shortly after Dr. Makary, a prominent surgeon and public health advocate, emerged as a central figure in the ‘Make…